dsm-firmenich Ventures Research
Investment Thesis
dsm-firmenich Ventures is the corporate venture capital arm of dsm-firmenich, the merged nutrition, beauty and health ingredients group formed from the 2023 combination of Royal DSM and Firmenich. The unit's stated mandate is "investing with purpose, investing in progress" -- pairing financial returns with strategic access to dsm-firmenich's scientific, technological and commercial infrastructure. It positions itself as a strategic-financial hybrid investor rather than a pure financial fund, seeking startups whose technology can plug into or extend dsm-firmenich's existing business units.
Sector Focus
Investment focus is explicitly aligned to dsm-firmenich's three consumer-facing business units, plus cross-cutting platform technology:
- Perfumery & Beauty -- skincare, suncare, fragrance and beauty ingredient innovation
- Taste, Texture & Health -- food and beverage ingredients, alternative proteins, flavor and texture technology
- Health, Nutrition & Care -- vitamins, dietary supplements, medical nutrition, microbiome and therapeutic devices
- Cross-sector technology platforms and digital tools (e.g. advanced/additive manufacturing) that serve multiple business units
Stage Focus
The firm invests across early-stage and growth-stage rounds, describing its role as supporting "founders from creation to successful market exit" -- in practice this spans seed/late-seed extensions through growth rounds, with reserve capital held back for follow-on participation in existing portfolio companies.
Check Size
Per-round check size is stated as roughly EUR 500k to EUR 5m, with additional capital reserved for follow-ons. The firm typically takes a minority stake of 5-25% per investment.
Lead Tendency
dsm-firmenich Ventures says it can either lead investment rounds or follow another investor's lead, and explicitly states a preference to syndicate deals alongside other institutional and strategic investors -- consistent with a corporate VC that wants co-investors bringing market discipline and follow-on capital.
Recent Activity
Activity confirmed via press coverage in 2026 includes:
- April 2026: Led a $6M seed extension in Cosaic (Zurich-based yeast-derived multifunctional food ingredient platform), alongside a Swiss family office, Kickfund, Navus Ventures and Zuercher Kantonalbank.
- May 2026: Continued participation as an existing investor in P2 Science's $23M round (green chemistry / beauty and personal-care ingredients), led by Sofinnova Partners alongside Emerald Technology Ventures and GS Futures.
These two rounds illustrate the firm's dual pattern of leading smaller strategic-fit rounds (Cosaic) and following on in larger syndicated rounds where it is an existing cap-table investor (P2 Science).
Portfolio Highlights
Since founding in 2001, the firm has backed more than 100 startups (145 investments per PitchBook) spanning ingredient science, biotech, alternative proteins and advanced manufacturing. Notable current and past portfolio companies include Vivici (precision-fermentation dairy proteins), Meatly (cultivated pet food), Chinova Bioworks (mushroom-derived natural preservatives), Rootine (personalized micronutrients), Inne (fertility hormone tracking), Hyalex (biomimetic cartilage implants), Athian (livestock carbon accounting), and several additive-manufacturing plays (Inkbit 3D, Voxel8, Adaptive 3D, AM Technologies, C3D Materials). Exits include Arecor, ChromaDex, Isobionics, Teleflex, EyePromise and OK Capsule.
Team
- Scott Horner, Managing Director -- leads the venturing team
- Amanda Donohue-Hansen, Investment Director
- Akshat Kshetrapal, Investment Director
- Arpesh Mehta, Investment Director
- Philip Mertens, Investment Principal
- Philip Hul, Senior Director Fund Operations
- Adrienne Zitka, Legal Counsel
- Iulian Baxan, Associate
- Maxime Overgaag, Associate
- Diana Pepels, Team Coordinator
The team spans sourcing/investing (directors, principal, associates), operations (fund operations director, coordinator) and dedicated in-house legal counsel -- a structure typical of an established corporate venturing arm running deal-by-deal review rather than a lean solo-GP fund.
Decision Process
Not publicly detailed, but the team structure (multiple investment directors reporting alongside a managing director, dedicated legal counsel, and fund operations staff) points to an investment-committee-style process rather than a single decision-maker. Partners regularly serve as advisors to and board members of portfolio companies, reflecting active post-investment involvement.
Founder Preferences
dsm-firmenich Ventures favors founders building technology that is strategically adjacent to dsm-firmenich's existing science and commercial channels -- ingredient science, biotech platforms, alternative proteins, and materials/manufacturing technology -- where the corporate parent's R&D, regulatory and go-to-market resources can accelerate the startup's path to scale.
Geographic Focus
The firm states an operating focus on North America and Europe, consistent with the geographic footprint of its most recent disclosed investments (Cosaic in Switzerland, P2 Science in the US).